The ACS Industry Symposium, Recent Advances in Drug Development will feature lectures by the world’s leading researchers and experts in pharma discussing key topics around this theme. The program includes keynote presentations, panel discussions and networking opportunities.
Prof. Mehta is a researcher in the area of chemical Sciences and presently University Distinguished Professor and Dr. K. Anji Reddy Chair at the University of Hyderabad. He has earlier held faculty positions at IIT Kanpur, University of Hyderabad (Professor, Dean, and Vice Chancellor-1994-1998) and the Indian Institute of Science Bangalore (Professor and Director 1998-2005). He has held the position of Srinivas Ramanujan Research Professor of Indian National Science academy (1992-1997), CSIR Bhatnagar Fellow (2005-2010), National Research Professor (2009-2014) and Eli Lilly-Jubilant Chair (2010-2015). He has also held visiting Chairs in over a dozen universities in India and overseas.
Prof. Mehta has published nearly five hundred research papers and mentored over hundred doctoral and post-doctoral fellows. He has served on the Editorial Board of over a dozen international journals in chemical sciences and delivered over three hundred named and other lectures worldwide. He is a recipient of over fifty prestigious medals and awards and conferred many D. Sc.(h.c) and D. Lit. (h.c) degrees by institutions in India and abroad. He currently serves on the Board of Directors and the Scientific Advisory Boards of several pharmaceutical companies.
Prof. Mehta is a Fellow of the Royal Society (FRS) and a Foreign Member of the Russian Academy of Sciences. He is also a Fellow of all the three Science Academies in India and the Third World Academy of Sciences (TWAS). In addition, he has been the President of Indian National Science Academy (1999-2002), International Council for Science (2005-2008) and Co-Chair of Inter Academy Council (2000-2005). He has been decorated by the President of India (Padma Shri, 2000), president of France (Chevalier de la Legion d"Honneur, 2005) and President of Germany (Cross of the Order of Merit, 2015).
J. Moses Babu currently is Senior Principle Scientist, AR&D in a Technical Leadership Role at the Integrated Product Development Organization, Dr. Reddy’s Laboratories Ltd. With the wealth of experience and expertise in the areas of NMR and Mass Spectrometry, he has helped to accelerate reverse engineering, sameness determination, and deficiency response for APIs and Finished Products.
He obtained his Ph.D. from IIT Bombay and joined the Discovery Research Foundation (DRF) of Dr. Reddy’s in 1993. At DRF, he was involved in the discovery of NCEs, led the AR&D department. He subsequently moved to Custom Pharmaceutical Services (CPS) in 2009 where he has been leading the Formulation and AR&D departments till his move to IPDO in 2015.
He has co-authored over 100 publications and has been a thesis advisor for 12 Ph.D. students at Andhra University and Jawaharlal Nehru Technological University in Hyderabad.
Dr. Braiuca obtained his Ph.D. in 2003 at the University of Triest in Italy, working on the study of enzyme-substrate interactions. He continued his academic research career working on biocatalysis in Italy with a short Postdoc experience at Strathclyde University in Glasgow. In 2007 he co-founded SPRIN Technologies SpA, participated by Mitsubishi Chemicals, and started working as Scientific Advisor for Biocatalysis, joining full time later as R&D Director. At SPRIN he worked on enzyme immobilisation, biocatalytic process development and solid phase protein synthesis establishing numerous collaborations globally with many pharmaceutical companies. In 2010 he moved to Business Development, focusing his efforts to commercialising immobilised enzymes and development services in the American market.
In 2011 he joined Johnson Matthey as Product Manager of the newly established biocatalysis business, being promoted 2 years later as Product Manager of the Chiral Technologies area comprising homogeneous hydrogenation chemocatalysis and biocatalysis.
Over the course of his career Paolo published more than 20 peer reviewed articles on scientific journals and several contributions to chemical industry’s publications.
Dr. Jagath Reddy Junutula joined Cellerant in April 2014 as a Vice President, Antibody Discovery & Development. Prior to joining Cellerant, Jagath was at Genentech for 13 years focusing on oncology drug discovery and development, including discovery and validation of targets for treatment of cancer; design, development and pre-clinical validation of antibody drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific antibody/protein based cancer immunotherapeutic platforms for treatment of different types of cancers. He developed a novel THIOMAB technology platform to generate site-specific antibody-drug conjugates (ADCs) to improve the therapeutic utility of antibodies. This technology has widely been accepted as a new standard for the development of therapeutic ADCs.
Dr. Junutula obtained his Ph.D. in 1997 from the Indian Institute of Science, Bangalore, India, and did post-doctoral research in Germany as an Alexander von Humboldt fellow and at Stanford University. He has authored 70 peer-reviewed publications/patents and has presented his work at numerous international conferences. Dr. Junutula serves as an editorial board member of leading journals, mAbs & ACS Medicinal Chemistry Letters. He served as a President (2010-2011) and Board Chairman (2013-2014) of EPPIC Global, a non-profit organization that fosters entrepreneurial mentoring, partnering and networking among pharma/biotech professionals.
Dr. Mansoor A. Khan served with the US FDA for over 11 years as the Director of Product Quality Research and a Senior Biomedical Research Scientist (SBRS) at CDER, where he helped develop regulatory policies for reviews and compliance, and led cmc review and research teams on product formulations and bioequivalence/biowaiver studies. He has recently joined Texas A&M University as Professor and Vice Dean at Rangel College of Pharmacy in College Station, TX. Prior to joining FDA in 2004, Dr. Khan was a Professor of Pharmaceutics and Director of Graduate Program in the School of Pharmacy at Texas Tech University Health Science Center. He earned his Ph.D. degree in Industrial Pharmacy from the St. John's University School of Pharmacy at New York in 1992. He has obtained his B.Pharm from Kakatiya University and M.Pharm in Pharmaceutical Technology from Andhra University. He has published over 275 peer-reviewed manuscripts, five texts including “Quality by Design for Biopharmaceutical Drug Product Development”, 25 book chapters and more than 250 invited presentations world-wide.
Dr. Khan has held several leadership positions at the American Association of Pharmaceutical Scientists (AAPS) including elected chair of pharmaceutics and drug delivery (PDD) and the founding chair of formulations design and development (FDD). He serves on the editorial board of Pharmaceutical Technology, International Journal of Pharmaceutics, AAPSPharmsciTech, and Drug Delivery and Translational Research. As a formulations’ expert, Dr. Khan served as FDA representative to EMA (European Medical Agency), WHO, USP, NIH, DoD, DARPA, NASA, and Bill and Melinda Gates Foundation. He also served as the science policy advisor to CDER Center Director where he helped resolve complex litigations of drug reviews and compliance with science. He led the chemistry review team that approved the first 3D printed tablets in August 2015. Dr. Khan has received outstanding alumnus award from St. Johns University, College of Pharmacy, Excellence Award from Texas A&M University Health Science Center, over fifteen FDA/CDER Team Excellence Awards, FDA/CDER Scientific Achievement Award, FDA/CDER Exemplary Performance Awards, and Outstanding First Reviews of Generic Products Award. Additionally he received the AAPS Research Achievement Award in Formulations Design and Development. He is also an AAPS and AAiPS Fellow. Dr. Khan currently serves as a consultant and expert witness for the FDA.
Dr. Krishna Kumar is Robinson Professor of Chemistry, Chairman of the Chemistry Department and Adjunct Professor of Biomedical Engineering at Tufts University. He is a Member of the Cancer Center at the Tufts Medical Center in Boston. His research interests span synthetic organic chemistry, chemical biology, medicinal chemistry, biophysics, and cell biology. A recognized expert in peptide therapeutics, he is also a co-founder of several startup companies. Kumar’s contributions to science, and in particular chemistry and medicine, have been recognized widely. He was named a DuPont Young Professor, recognized as one of the top 35 young innovators in the world by MIT Technology Review magazine (TR35), awarded a Global Indus Technovator award from MIT-IBC, is a recipient of the National Science Foundation CAREER award, Technology award from the Massachusetts Technology Transfer Center, Excellence in Chemical Sciences Award from the Indian Society for Chemistry and Biology and was elected a Fellow of the American Association of the Advancement of Science (AAAS). He is a regular consultant to biotech and pharmaceutical companies.
Dr. Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry since September 2002. He leads the company’s chemistry department, which carries out research in antibody-drug conjugate technologies, the development of potent drug payloads, novel linker systems, conjugation methodology, mechanism of action studies, and the development of glycan modified antibody structures. Prior to joining Seattle Genetics, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dana-Farber Cancer Institute, Harvard Medical School.
Dr. Senter received an A.B. in Biochemistry from the University of California, Berkeley, a Ph.D. in Chemistry from the University of Illinois, and did postdoctoral research at the Max Planck Institute of Experimental Medicine in Göttingen, Germany. He is the Senior Editor of Molecular Cancer Therapeutics (AACR) and serves as an Affiliate Professors of Bioengineering at the University of Washington, and Pharmaceutical Sciences at the University of Southern California. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored more than 150 scientific publications and holds more than 40 patents.
Prof. Dr. Anamik Shah is a senior faculty member and first Ph.D. scholar at the Department of Chemistry, Saurashtra University, Rajkot. Prof. Shah teaches Organic, Medicinal, Environmental and Pharma Analytical Chemistry. Prof. Shah is also vice-chancellor of Gujarat Vidyapith in Ahmedabad.
Prof. Shah is an academic researcher who pioneered industry-academic linkages, by working in several projects on Drug Discovery & Process Chemistry. He has been granted a project of Rs. 13.19 Crore for the establishment of "Center of Excellence" at National Facility for Drug Discovery Complex, Saurashtra University, Rajkot. Additionally, he has been funded by the National Institute of Health (NIH)-USA and the Department of Atomic Energy-BRNS, National Medicinal Plant Board-New Delhi on diversified fields of medicinal chemistry drug research on anti-HIV, anticancer and anti- tubercular and multi resistance riveters (MDRR). He has also established unique facility for Preservation of Molecular Diversity [FPMD] through flagship project, from MSME, DST. He is currently a President of the Indian Society of Chemists and Biologists.
Professor Shah completed his degree of Doctor of Philosophy (Chemistry) in 1983, Master of Science in 1977, and Special LLB in 1988. He was awarded by International Scientific Partnership Foundation, Russia and other awards for his notable contribution in field of Pharmaceutical Research.
Dr. Raj Suryanarayanan (Sury) is Professor and William and Mildred Peters Endowed Chair in the College of Pharmacy, University of Minnesota. He obtained his B.Pharm. and M.Pharm. degrees from Banaras Hindu University, India and M.Sc. and Ph.D. degrees in Pharmaceutics from the University of British Columbia, Vancouver, Canada. The overall goal of his research is to apply principles of pharmaceutical materials science to the design of robust pharmaceutical dosage forms with reproducible and predictable properties. His research group has developed low temperature powder X-ray diffractometric techniques to study frozen and freeze-dried pharmaceutical systems. He is a consultant to numerous pharmaceutical companies and was a member of the USP Expert Committee (Excipients test methods). He is a fellow of the American Association of Pharmaceutical Scientists (AAPS) and is a past chair of the Teachers of Pharmaceutics Section of the American Association of Colleges of Pharmacy. Sury is a member of the Academy of Distinguished Teachers at the University of Minnesota, the recipient of the Outstanding Educator Award from AAPS, and the David Grant Research Achievement Award in Physical Pharmacy as well as the PhRMA (Pharmaceutical Research and Manufacturers of America) Foundation Award. He is also an Associate Editor of Molecular Pharmaceutics.
Dr. Ming-Wei Wang obtained his medical degree from Shanghai Medical University in 1982. Following a practice as an orthopedic surgeon in Shanghai, he attended UCLA School of Medicine and the Institute of Animal Physiology at Cambridge, U.K. He was awarded a Ph.D. degree in physiology by University of Cambridge in 1989 and started his research career in several US-based biotechnology companies, including Amylin Pharmaceuticals and Ligand Pharmaceuticals. He was heavily involved in entrepreneur activities and co-funded several biopharmaceutical start-up companies in the U.S., U.K., China and Hong Kong.
Dr. Wang was appointed as a professor of pharmacology at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS) and executive deputy director of the Chinese National Center for Drug Screening in 2001. The WHO/TDR named him as one of the 12 expert members for the Thematic Reference Group on Innovation and Technology, Shanghai Clinical Research Center appointed him as a Senior Advisor on International Business Affairs and Chinese Academy of Medical Sciences/Peking Union Medical College made him Guest Professor.
Dr. Wang has published more than 170 research papers, received a number of academic awards or social honors from the U.K., U.S., Taiwan and China, and obtained 63 international patents. Dr. Wang’s research achievements include the discovery of the first non-peptidic glucagon-like peptide-1 receptor agonist (Boc5), the determination of the 3-D structure of the human glucagon receptor (in collaboration with Dr. Raymond C. Stevens) and its conformational states (jointly with Drs. Hualiang Jiang and Raymond C. Stevens), the elucidation of the insulinotrophic effect of insulin-like peptide 5 (INSL5) as well as the identification of the oncologic link of GPR160, an orphan G-protein coupled receptor.
Dr. Reddy's Institute of Life Sciences, India
Glenmark Pharmaceuticals, India
CSIR-Indian Institute of Integrative Medicine, India
Dr. Reddy’s Laboratories, India
Newreka Green Synth Technologies Pvt. Ltd., India
CSIR-National Chemical Laboratory, India
University of Delhi, India